| Notes: |
| 1. |
The audited financial results as reviewed by the Audit Committee have been approved by the Board at its meeting held on May 9, 2011. |
| 2. |
The consolidated audited financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement', AS-27' Financial Reporting of Interests in Joint Ventures' and includes audited financial results of all subsidiaries and Joint Ventures. |
| 3. |
The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'. |
| 4. |
Investor complaints pending at the beginning of the quarter: Nil, received:122, resolved: 122 and lying unresolved at the end of the quarter Nil. |
| 5. |
FOB value of exports is Rs.26970 million (Rs.20864 million). |
| 6. |
Sales include dossier income in standalone of Rs.2321 million (Rs.1179 million) and in consolidated of Rs.2556 million (Rs.1977 million). |
| 7. |
Foreign Exchange Gain for the year represents exchange differences arising on all foreign currency transactions. This includes net gain due to restatement, conversion and buyback of Foreign Currency Convertible Bonds (net of Deposits) Rs.85 million (Rs.1139 million). |
| 8. |
The Group has sold its entire stake in Cephazone Pharma LLC, a joint venture of one of its overseas subsidiaries in USA. Also, the Company has entered into a definitive agreement to divest its 80.50% stake in one of its 100% subsidiaries namely Aurobindo Datong Bio Pharma Co. Ltd., China (ADBPL) effective November 30, 2010. Thus the Company's balance stake of 19.50% in ADBPL will be strategic in nature to ensure uninterrupted supply of raw materials at competitive prices. |
| 9. |
Exceptional item for the current year ended March 31, 2011 relates to loss (net) on sale of subsidiaries and joint ventures (including loss (net) aggregating to Rs.287 million and Rs.77 million disclosed respectively in standalone and consolidated results in respect of sale of entities referred in para 8 above). Previous year exceptional item relates to gain on buy back of FCCBs. |
| 10. |
The Equity shares of the Company with face value of Rs.5/- per share have been subdivided into 5 shares of Re.1/- each effective February 11, 2011, being the record date for the said purpose. Consequently, the Basic and Diluted Earning Per Share and shareholding data of the Previous Year have been re-computed and disclosed accordingly. |
| 11. |
In respect of matter referred to in the auditors' report for the year ended March 31, 2011 in relation to non-provision of premium on redemption of 139,200 Zero Coupon Foreign Currency Convertible Bonds (FCCBs) of USD 1000 each, the management has taken the consisent view that it can not be determined being contingent in nature, as determination and crystallization of liabilities is dependant on uncertain future events or actions, not wholly within the control of the Company. |
| 12. |
In respect of matter referred to in the auditors' report on consolidated financial statements for the year ended March 31, 2011, in relation to non-confirmity with AS- 22 "Accounting for Taxes on Income" in the case of certain overseas subsidiaries and joint venture entities, the management believes that presently it is not practicable to measure deferred tax in respect of said entities using the measurement principles prescribed under aforesaid AS-22. |
| 13. |
The Board recommended final dividend @100% on the equity share capital of the Company i.e Re.1/- per share subject to approval of members. This is in addition to interim dividend @100% on equity share capital of the Company i.e.Rs.5/- per share paid in November 2010. |
| 14. |
The figures for the previous year have been rearranged/regrouped wherever necessary. |
